| Title of Invention | A MUTATED G-CSF mRNA OR cDNA FRAGMENT OR PROTEIN AS A DIAGNOSTIC CANCERMARKER |
|---|---|
| Abstract | This invention relates to a mutated G-CSF mRNA or cDNA fragment iiaving a deletion of an exon 3 region for use as a diagnostic cancermarker. |
| Full Text | ABSTRACT 876/CHENP/2004 "A mutated G-CSF mRNA or cDNA fragment or protein as a diagnostic cancermarker' This invention relates to a mutated G-CSF mRNA or cDNA fragment iiaving a deletion of an exon 3 region for use as a diagnostic cancermarker. WE CLAIM: 1. A mutated G-CSF mRNA or cDNA fragment having a deletion of an exon 3 region for use as a diagnostic cancermarker. 2. A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region for use as a diagnostic cancermarker. 3. A microarray for diagnosis of cancer comprising (a) a DNA fragment corresponding to exon 3 of a G-CSF gene, and (b) at least one of DNA fragments corresponding to exons 1, 2, 4 and 5 of said G-CSF gene are bound. 4. A diagnostic agent for cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein. 5. A microarray for diagnosis of cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein. 6. A primer for use in amplification of a G-CSF gene in a G-CSF nucleic acid sample obtained from mammalian tissues or cells, wherein said primer is selected from the group consisting of the following nucleotide sequence pairs: sense: 5'-ACCCCCCTGGGCCCTGCC-3' (SEQ ID NO. 1) and antisense: 5'-TCAGGGCTGGGCAAGGTG-3' (SEQ ID NO. 2); sense: 5'-ACCCCCCTGGGCCCTGCC-3' (SEQ ID NO. 1) and antisense: 5'-CAGCTGCAGGGCCTGGCT-3' (SEQ ID NO 5); sense: 5'-ACCCCCCTGGGCCCTGCC-3' (SEQ ID NO. 1) and antisense: 5'-CGCTATGGAGTTGGCTCAAGC-3' (SEQ ID NO. 6); sense: 5'-ACCCCCCTGGGCCCTGCC-3' (SEQ ID NO. 1) and antisense: 5'-CAGCTTCTCCTGGAGCGC-3' (SEQ ID NO. 9); sense: 5'-ATCCAGGGCGATGGCGCAGCG-3' (SEQ ID N0.3) and antisense: 5'-TCAGGGCTGGGCAAGGTG-3' (SEQ ID NO. 2); sense: 5'-ATCCAGGGCGATGGCGCAGCG-3' (SEQ ID N0.3) and antisense: 5'-CAGCTGCAGGGCCTGGCT-3' (SEQ ID NO. 5); sense: 5'-ATCCAGGGCGATGGCGCAGCG-3' (SEQ ID N0.3) and antisense: 5'-CGCTATGGAGTTGGCTCAAGC-3' (SEQ ID NO. 6); sense: 5'-TGTGCCACCTACAAGCTGTGC-3' (SEQ ID N0.4) and antisense: 5'-TCAGGGCTGGGCAAGGTG-3' (SEQ ID NO. 2); sense: 5'-TGTGCCACCTACAAGCTGTGC.3' (SEQ ID N0.4) and antisense: 5'-CAGCTGCAGGGCCTGGCT-3' (SEQ ID NO. 5); and sense: 5'-TGTGCCACCTACAAGCTGTGC-3' (SEQ ID N0.4) and antisense: 5'-CGCTATGGAGTTGGCTCAAGC-3' (SEQ ID NO. 6). 7. A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region. 8. An antibody specifically binding to the mutated G-CSF protein as claimed in claim 7. 9. The antibody as claimed in claim 8, wherein the antibody is a polyclonal antibody. 10. The antibody as claimed in claim 8, wherein the antibody is a monoclonal antibody. |
|---|
| Patent Number | 229687 | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 876/CHENP/2004 | ||||||||||||||||||||||||
| PG Journal Number | 13/2009 | ||||||||||||||||||||||||
| Publication Date | 27-Mar-2009 | ||||||||||||||||||||||||
| Grant Date | 19-Feb-2009 | ||||||||||||||||||||||||
| Date of Filing | 26-Apr-2004 | ||||||||||||||||||||||||
| Name of Patentee | MEDIGENES | ||||||||||||||||||||||||
| Applicant Address | #1822, HYUNDAI VENTURE VILL B/D, 713 SUSEO-DONG, GANGNAM-GU, SEOUL 135-539, | ||||||||||||||||||||||||
Inventors:
|
|||||||||||||||||||||||||
| PCT International Classification Number | C12N15/12 | ||||||||||||||||||||||||
| PCT International Application Number | PCT/KR02/01825 | ||||||||||||||||||||||||
| PCT International Filing date | 2002-09-28 | ||||||||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||||||||